Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000041767 | SCV000065463 | benign | not specified | 2010-05-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000041767 | SCV000169773 | benign | not specified | 2011-07-05 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Eurofins Ntd Llc |
RCV000041767 | SCV000231957 | benign | not specified | 2016-08-02 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001509630 | SCV001472470 | benign | not provided | 2020-01-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001509630 | SCV001716453 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002496662 | SCV002795416 | benign | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2021-08-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450796 | SCV004183047 | benign | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001276147 | SCV004183048 | benign | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Dept Of Ophthalmology, |
RCV003887900 | SCV004707209 | benign | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Breakthrough Genomics, |
RCV001509630 | SCV005287594 | benign | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001276147 | SCV001462000 | benign | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |